Splenic Marginal Zone Lymphoma Clinical Trial
— MALIBUOfficial title:
MALIBU Trial - Phase II Study of Combination Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
Verified date | May 2023 |
Source | International Extranodal Lymphoma Study Group (IELSG) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Single-arm, phase II clinical trial of patients with Extranodal Marginal Zone Lymphoma (EMZL). It is planned to recruit 130 patients. Additional patients with Splenic Marginal Zone Lymphoma (SMZL), up to 30, and Nodal Marginal Zone Lymphoma (NMZL), up to 15, will be included in the trial in order to preliminary explore the clinical activity and safety of the combination treatment proposed. The study primary endpoints will be analysed on the EMZL population. Outcome of patients with SMZL and NMZL will be analysed and reported separately
Status | Active, not recruiting |
Enrollment | 175 |
Est. completion date | June 15, 2027 |
Est. primary completion date | June 15, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Chemotherapy and immunotherapy-naïve, symptomatic and in need of treatment patients, with histologically proven CD20-positive MZL, not eligible for local therapy, including: 1. EMZL (MALT Lymphoma) patients with MALT- IPI score 1-2 in need of systemic therapy. Either de novo or relapsed following local therapy (including surgery, radiotherapy and antibiotics for H. pylori-positive gastric lymphoma) arisen at any extranodal site with MALT-international prognostic index (IPI) score 1-2 at the time of study entry. 1.1.The following patients with gastric MALT Lymphoma can be entered: 1. H. pylori-negative cases, either de novo (non pretreated) or at relapse following local therapy (i.e., surgery, radiotherapy or antibiotics). 2. H. pylori-positive cases at diagnosis, who either first line antibiotics or further local treatment (surgery or radiotherapy), including patients with: - clinical (endoscopic) and histological evidence of disease progression at any time post H. pylori eradication; - clinical (endoscopic) and histological relapse (without H. pylori re-infection), after a remission patients; - persistent (stable) lymphoma at = 1 year post H. pylori eradication. 1.2. Similar consideration may be applied to patients with ocular adnexal lymphoma treated with antibiotics. 2. SMZL patients in need of therapy. Either de novo or relapsed following local therapy [including surgery and antiviral therapy for Hepatitis C virus (HCV)]. Patient must have a symptomatic disease requiring treatment and be not eligible for splenectomy or not willing to undergo splenectomy. 2.1. Patients with SMZL can be entered if any of the following criteria is present: 1. bulky progressive or painful splenomegaly; 2. enlarged lymph nodes or involvement of extranodal sites with or without cytopenias , i.e. involvement of =3 nodal sites, each with a diameter of =3 cm. Any nodal tumor mass with a diameter of =7 cm (GELG criteria, as adopted in follicular lymphoma); 3. one of the following symptomatic/progressive cytopenias: - Hgb < 10 g/dL; - ANC < 1000/µL: - PLT< 80 000/µL whatever the reason (autoimmune or hypersplenism or bone marrow infiltration). 2.2. Splenectomised patients with rapidly raising lymphocyte counts, lymphadenopathy or involvement of extranodal sites can be entered. 2.3. SMZL with concomitant HCV infection who have not responded to or are relapsed after antiviral therapy can be entered. 3. NMZL patients in need of therapy Either, de novo presenting with disseminated disease or relapsed after local radiotherapy or following antiviral therapy for HCV. Localized nodal MZL is not eligible. - Measurable or evaluable disease. - Ann Arbor II-IV. Stage I disease may be eligible only if not candidate to local therapy (surgery or radiotherapy). - Age = 18. - Life expectancy of at least 1 year. - ECOG Performance status 0-2. - Adequate bone marrow, kidney and liver function - For women of childbearing potential only: negative serum pregnancy test done within 7 days prior to study drugs administration or within 14 days if with a confirmatory urine pregnancy test within 7 days prior to the first study drugs administration. - Fertile male or female patients of childbearing potential and their partners must use higly effective contraception methods during the study and for at least 12 months after the last dose of subcutaneous rituximab. In case hormonal methods of birth control is used a barrier method must be added. - Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: 1. Any type of lymphoma other than MZL (including MZL with histologic transformation to high-grade lymphoma). 2. Localized (stage IE and IIE) MALT lymphoma, for example gastric, ocular and cutaneous lymphoma, that may benefit from local therapy only (surgery or radiotherapy). 3. Known CNS involvement of MZL. 4. Any previous systemic treatment with immunotherapy or chemotherapy or with BTK inhibitors. 5. Major surgery within 4 weeks prior to registration. 6. History of stroke or intracranial bleeding within 6 months. 7. Known bleeding diathesis (eg, von Willebrand's disease) or hemophilia. 8. Concurrent use of warfarin of other vitamin K antagonists. 9. Concurrent use of strong cytochrome P450 (CYP)3A4/5 inhibitors (see http://medicine.iupui.edu/clinpharm/ddis/clinical-table/). 10. Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk. 11. International normalized ratio (INR) or prothrombin time (PT) =1.5 ULN. Partial thromboplastin time (PTT) or activated PTT (aPTT) =1.5 ULN unless due to lupus anticoagulant. 12. Vaccinated with live, attenuated vaccines within 4 weeks prior to randomization. 13. Clinically significant hypersensitivity (e.g., anaphylactic or anaphylactoid reactions to the compound of ibrutinib and/or rituximab themselves or to the excipients in their formulation). 14. Positive test results for chronic HBV infection (defined as positive HBsAg serology). 15. Patients with occult or prior HBV infection (defined as negative HBsAg and positive total HBcAb) may be included if HBV DNA is undetectable, provided that they are willing to undergo monthly DNA testing and taking specific antiviral prophylaxis, according to local policy. Patients who have protective titers of hepatitis B surface antibody (HBsAb) after vaccination are eligible. 16. Positive test results for hepatitis C. Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA. 17. HIV infection or immunodeficiency. 18. Active, severe infections 19. Pregnancy or breastfeeding. 20. Clinically significant cardiovascular diseases such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification. 21. Any serious medical or psychiatric illness likely to interfere with participation in this clinical study. 22. Prior history of malignancies other than MZL within 3 years,with the exception of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer. 23. Current enrolment or participation in another therapeutic clinical trial within 28 days prior to treatment start |
Country | Name | City | State |
---|---|---|---|
Belgium | CHU UCL Namur / site Godinne | Yvoir | |
France | Institut Bergonié | Bordeaux | |
France | IHBN - CHU Côte de Nacre | Caen | |
France | CHU d'Estaing | Clermont-Ferrand | Cedex 1 |
France | CHU Dijon Bourgogne - Hôpital François Mitterand | Dijon | |
France | CHU de Grenoble - Hôpital Albert MICHALLON | La Tronche | |
France | CHU de Montpellier | Montpellier | Cedex 05 |
France | Saint Louis Hospital | Paris | |
France | Centre Hospitalier Lyon Sud | PIERRE-BENITE Cedex | |
France | CHU de Rennes Pontchaillou | Rennes | Cedex 9 |
France | CHRU de Strasbourg | Strasbourg | |
France | IUCT Oncopole Toulouse | Toulouse | |
France | CHU de Tours - Hôpital Bretonneau | Tours | Cedex 01 |
France | CHU de Nancy - Hôpital Brabois | Vandœuvre-lès-Nancy | |
Italy | Azienda Ospedaliera Universitaria Ospedali Riuniti - Università Politecnica delle Marche | Ancona | |
Italy | IRCCS Centro di Riferimento Oncologico di Aviano | Aviano | PN |
Italy | Giovanni Paolo II/I.R.C.C.S. Istituto Tumori | Bari | |
Italy | A.O. Spedali Civili di Brescia | Brescia | |
Italy | Ospedale Oncologico Businco | Cagliari | |
Italy | AAST Grande Ospedale Metropolitano Niguarda | Milano | |
Italy | Fondazione IRCCS - Cà Granda - Ospedale Maggiore Policlinico | Milano | |
Italy | Fondazione IRCCS - Istituto Nazionale dei Tumori | Milano | |
Italy | Ospedale San Raffaele | Milano | MI |
Italy | Fondazione IRCCS - Policlinico San Matteo | Pavia | |
Italy | Ospedale degli Infermi | Ponderano | BI |
Italy | U.O. Ematologia AUSL Ravenna | Ravenna | |
Italy | Azienda Ospedaliera Arcispedale Santa Maria Nuova IRCCS | Reggio Emilia | |
Italy | Università degli Studi di Roma La Sapienza | Roma | |
Italy | A.O.U. Città della Salute e della Scienza di Torino Ospedale Molinette | Torino | TO |
Italy | Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) | Trieste | |
Italy | Ospedale di Circolo e Fondazione Macchi di Varese | Varese | |
Portugal | Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. | Lisboa | |
Switzerland | Kantonalspital Baden | Baden | |
Switzerland | Istituto Oncologico della Svizzera Italiana (IOSI) | Bellinzona | TI |
Switzerland | Inselspital Bern | Bern | |
Switzerland | Hôpitaux Universitaires de Genève | Genève | |
Switzerland | Universitätsspital Zürich | Zürich |
Lead Sponsor | Collaborator |
---|---|
International Extranodal Lymphoma Study Group (IELSG) |
Belgium, France, Italy, Portugal, Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complete Response Rate at 12 months | The proportion of patients with complete response after 12 months from treatment start | 12 months after treatment start | |
Primary | Progression Free Survival at 5 years | The proportion of patients without disease progression after 5 years from treatment start | 5 years from treatment start | |
Secondary | Number of treatment-Emerging Adverse Events | Analysis of incidence, severity and relationship of adverse events graded according to NCI Common Toxicity Criteria, version 4.0 | From the time of informed consent signature until 28 days after treatment discontinuation or until resolution of all treatment-related AEs, whichever occurs later | |
Secondary | Complete Response Rate at 24 months | The proportion of patients with complete response after 24 months from treatment start | 24 months from treatment start | |
Secondary | Overall Response Rate at 12 and 24 months | The proportion of responding patients (partial and complete responses) assessed at 12 and 24 months after treatment start | 12 and 24 months after treatment start | |
Secondary | Overall survival | The time from the date of treatment start to the date of death from any cause | From the date of treatment start to the date of death due to any cause until 5 years from treatment discontinuation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
Completed |
NCT02254772 -
A Phase I/II Study of Intratumoral Injection of SD-101
|
Phase 1/Phase 2 | |
Completed |
NCT01427881 -
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
|
Phase 2 | |
Completed |
NCT01701232 -
Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma
|
Phase 3 | |
Completed |
NCT01233921 -
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
|
N/A | |
Completed |
NCT01093586 -
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 2 | |
Completed |
NCT00078858 -
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
|
Phase 1/Phase 2 | |
Completed |
NCT00003196 -
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma
|
N/A | |
Terminated |
NCT01678443 -
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT01815749 -
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma
|
Phase 1 | |
Withdrawn |
NCT02281279 -
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Terminated |
NCT01408043 -
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
|
N/A | |
Withdrawn |
NCT01238146 -
Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT00608361 -
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
|
Phase 1 | |
Terminated |
NCT00288067 -
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT00098891 -
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00438880 -
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT00118170 -
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function
|
Phase 1 | |
Completed |
NCT00026182 -
Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
|
Phase 2 | |
Completed |
NCT00004241 -
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
|
Phase 1 |